Exhibit 3.1
CERTIFICATE OF AMENDMENT
OF
RESTATED CERTIFICATE OF INCORPORATION
OF
SYROS PHARMACEUTICALS, INC.
Syros Pharmaceuticals, Inc. (the Corporation), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the General Corporation Law), does hereby certify as follows:
1. | The name of the Corporation is Syros Pharmaceuticals, Inc. |
2. | Article FOURTH of the Restated Certificate of Incorporation of the Corporation, as amended, is hereby amended by replacing the first paragraph thereof with the following: |
FOURTH: The total number of shares of all classes of stock which the Corporation shall have authority to issue is 710,000,000 shares, consisting of (i) 700,000,000 shares of Common Stock, $0.001 par value per share (Common Stock) and (ii) 10,000,000 shares of Preferred Stock, $0.001 par value per share (Preferred Stock).
3. | This Certificate of Amendment has been duly adopted by the Board of Directors and stockholders of the Corporation in accordance with Section 242 of the General Corporation Law. |
[The remainder of this page is intentionally left blank.]
IN WITNESS WHEREOF, the Corporation has caused its duly authorized officer to execute this Certificate of Amendment on this 15th day of September, 2022.
SYROS PHARMACEUTICALS, INC. | ||
By: | /s/ Nancy Simonian | |
Name: Nancy Simonian, M.D. | ||
Title: President and Chief Executive Officer |